Driving clinical impact
Faster, leaner, de-risked
Product portfolio
Galenicap is building a scalable product development engine turning validated science into real solutions for patients. Our approach combines strategic product selection, cost-efficient and agile development, and focused investment to accelerate the path toward clinical validation.
​
Today, we have 10+ active programs in multiple, high-impact indications, including CNS, stroke, oncology, cardiovascular conditions, infectious diseases, obesity, and women’s health.
We turn validated science - often trapped in academia or missed commercially - in real solutions for patients
Everyone counts
Our vision is to improve healthcare by expanding access to affordable, patient-centered medicines.
At Galenicap, we are deeply committed to responsible business practices rooted in strong governance and meaningful social impact. We champion health equity, fair medicine pricing, transparent leadership, and a culture of diversity and inclusion.
We are proud that our team members, collaborators, partners, and shareholders are united in upholding these values.
Latest news & events
Galenicap BV and Neurevo GmbH created Glicothera BV, a specialty pharma focused on a new neuroprotective agent for stroke
May 13, 2025
Galenicap co-founded Aclathera BV, a specialty pharma dedciated to the development of new cancer treatments
March 28, 2025
Clozathera BV (a Galenicap company) completes financing round to support Phase 1 clinical trial for its lead product
January 6, 2025